Member? Log in...

Join or renew today

Login

Understanding the COVID-19 plasma treatment debate

By forcing the Food and Drug Administration on Aug. 23, 2020, to approve blood plasma as a COVID-19 treatment under an emergency use authorization (EUA), President Trump again inserted politics into scientific research ― a situation that may create even more uncertainty about plasma as a potential treatment.

Plasma ― the part of blood that contains antibodies and proteins ― is still under investigation for this use, and those leading randomized clinical trials now far they may have difficulty recruiting new patients due to the controversy.

The page you have requested is available to AHCJ members only. If you are a member, please login below.

If you're not a member, we invite you to join us. Read about member benefits and how to join.